DBDouglas G. Batt

Douglas G. Batt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Douglas G. Batt has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Dilip P. Modi

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication
  • Frank A. Barbera

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication
  • Gary A. Cain

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication
  • Gregory C. Houghton

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication
  • Joseph J. Petraitis

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication
  • Mark S. Forsythe

    DuPont Pharmaceuticals Company, P.O. Box 80500, Wilmington, Delaware 19880-0500

    1 shared publication

Latest Publications

  • Disubstituted Indazoles as Potent Antagonists of the Integrin αvβ3

    by Douglas G. Batt, Joseph J. Petraitis, Gregory C. Houghton, Dilip P. Modi, Gary A. Cain, Martha H. Corjay, Shaker A. Mousa, Peter J. Bouchard, Mark S. Forsythe, Patricia P. Harlow, et al.

    A new series of indazole-containing αvβ3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 293 cells to fibrinogen and to selectivity for αvβ3 over GPIIbIIIa, another RGD-binding integrin. Indazoles attached to a 2-aminopyridine or 2-aminoimidazole by a propylene linker at the indazole 1-position and to a diaminopropionate derivative via a 5-carboxylate amide provided the best potency with moderate selectivity. Several differences in the SAR of the diaminopropionate moiety were observed between this series and a series of isoxazoline-based selective GPIIbIIIa antagonists. Compound 34a (SM256) was a potent antagonist of αvβ3 (IC50 2.3 nM) with 9-fold selectivity over GPIIbIIIa.